Literature DB >> 27807907

Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study.

Anne Bénard-Laribière1,2, Pernelle Noize2,3,4, Elodie Pambrun1,2, Fabienne Bazin1,2, Hélène Verdoux1,2,5, Marie Tournier1,2,5, Bernard Bégaud1,2,3, Antoine Pariente1,2,3,4.   

Abstract

PURPOSE: To study trends in incident use of benzodiazepines in France between 2006 and 2012.
METHODS: A cross-sectional study repeated yearly was conducted using data from the French national healthcare insurance system. New benzodiazepine users were defined as users without any benzodiazepine dispensing in the year prior to the first dispensing of benzodiazepine in each year. Relative changes in incidence of use were calculated with the year 2006 as reference; confidence intervals for changes were estimated using the bootstrap method.
RESULTS: Over the study period, the incident use of benzodiazepines decreased from 6.2% to 5.9%; this corresponded to a 5.1% decrease (95%CI: -6.8% to -4.2%) for 2012 compared to 2006. The decrease mainly concerned hypnotics (-15.5%; -21.2% to -15.3%) and appeared more pronounced in people aged 18-44 years. Incident use of anxiolytics remained stable overall during the period (4.0% of the population). Within anxiolytics, incident use of long half-life benzodiazepines (bromazepam, prazepam) decreased in favor of short half-life benzodiazepines (alprazolam, oxazepam). This change concerned patients aged 65-79 and patients aged 80 years and over. Nevertheless, in 2012, nearly one third of incident users aged 65 years and over started a treatment with a long half-life benzodiazepine, mostly bromazepam.
CONCLUSIONS: A limited decrease in incident benzodiazepine use was observed in France between 2006 and 2012 that concerned only hypnotics. Although congruent with recommendations, this improvement appears insufficient with regard to the level of exposure to these drugs in France. New actions especially targeting anxiolytic benzodiazepine use should be undertaken to consolidate these results.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  benzodiazepines; drug utilization; incidence; insurance health reimbursement; pharmacoepidemiology

Mesh:

Substances:

Year:  2016        PMID: 27807907     DOI: 10.1002/pds.4123

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  14 in total

1.  Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.

Authors:  Damien Driot; Emilie Jouanjus; Stéphane Oustric; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

2.  Potentially inappropriate medication use by level of polypharmacy among US Veterans 49-64 and 65-70 years old.

Authors:  Jordan Guillot; Christopher T Rentsch; Kirsha S Gordon; Amy C Justice; Julien Bezin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-07-15       Impact factor: 2.732

3.  Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; John D Fisk; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; James J Marriott; Charles N Bernstein
Journal:  Front Neurol       Date:  2022-04-14       Impact factor: 4.086

4.  Changes in Australian Early-Career General Practitioners' Benzodiazepine Prescribing: a Longitudinal Analysis.

Authors:  Parker Magin; Amanda Tapley; Adrian J Dunlop; Andrew Davey; Mieke van Driel; Elizabeth Holliday; Simon Morgan; Kim Henderson; Jean Ball; Nigel Catzikiris; Katie Mulquiney; Neil Spike; Rohan Kerr; Simon Holliday
Journal:  J Gen Intern Med       Date:  2018-07-23       Impact factor: 5.128

5.  Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015.

Authors:  Cathal A Cadogan; Cristín Ryan; Caitriona Cahir; Colin P Bradley; Kathleen Bennett
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

6.  High prevalence of prescription of psychotropic drugs for older patients in a general hospital.

Authors:  Inken Arnold; Kati Straube; Wolfgang Himmel; Stephanie Heinemann; Vivien Weiss; Laura Heyden; Eva Hummers-Pradier; Roland Nau
Journal:  BMC Pharmacol Toxicol       Date:  2017-12-04       Impact factor: 2.483

7.  Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013.

Authors:  Simon J C Davies; Binu Jacob; David Rudoler; Juveria Zaheer; Claire de Oliveira; Paul Kurdyak
Journal:  Ther Adv Psychopharmacol       Date:  2017-12-05

8.  Anticholinergic and sedative drug burden in community-dwelling older people: a national database study.

Authors:  Catherine J Byrne; Caroline Walsh; Caitriona Cahir; Cristín Ryan; David J Williams; Kathleen Bennett
Journal:  BMJ Open       Date:  2018-07-06       Impact factor: 2.692

9.  Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle.

Authors:  Clarice S Madruga; Thales L Paim; Hamer N Palhares; Andre C Miguel; Luciana T S Massaro; Raul Caetano; Ronaldo R Laranjeira
Journal:  Braz J Psychiatry       Date:  2018-10-11       Impact factor: 2.697

10.  Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.

Authors:  Anna Sidorchuk; Kayoko Isomura; Yasmina Molero; Clara Hellner; Paul Lichtenstein; Zheng Chang; Johan Franck; Lorena Fernández de la Cruz; David Mataix-Cols
Journal:  PLoS Med       Date:  2018-08-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.